|
| |
Haemacure CorporationHaemacure Corporation is a leader in the development and commercialization of innovative and clinically effective biological adhesives, biomaterials and surgical devices for a broad range of applications in the acute surgical wound care market.
Haemacure Corporation was founded in 1991 and completed its initial public offering in Canada in June 1996, raising C$28 million. Haemacure Corporation is traded under the symbol HAE on the Toronto Stock Exchange.
Haemacure’s head office is located in Montreal and it operates a wholly-owned subsidiary in Sarasota, Florida where the sales, marketing, medical and regulatory affairs offices are located.
Haemacure has devoted considerable resources to the research and development of a unique process to extract fibrinogen and thrombin from human plasma, resulting in Haemacure's fibrin sealant core technology. Fibrin sealant is a tissue glue with hemostatic, sealing and adhesive properties. It can be used in a variety of surgical procedures to arrest bleeding, seal tissues and act as an adjunct to wound healing.
| Contact Details: |
| 400 Wood Road |
| Braintree |
| MA |
| 02184 |
| United States of America |
| Tel: | 514 426 7181 |
| Fax: | 514 630 7756 |
| Email: | khammes@haemacurecorp.com |
| WWW: | www.haemacure.com/
|
|
Loading...
|
Press Releases on Haemacure Corporation:
|
 |
| Angiotech Pharmaceuticals, Inc. announces financial results for the third quarter ended September 30, 2009 |
9th November, 2009 |
Angiotech Pharmaceuticals, Inc. |
VANCOUVER, Nov. 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the third quarter ended September 30, 2009.
"We were
|
| Haemacure announces its presentation at the Rodman Renshaw 11th Annual Healthcare Conference |
8th September, 2009 |
Haemacure Corporation |
HAE: TSX
MONTREAL, Sept. 8 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company, announces that its Chairman and CEO, Mr. Joseph Galli, will present at the
|
| Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results |
11th June, 2009 |
HAEMACURE CORPORATION |
HAE:TSX
MONTREAL, June 11 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE) released today the results of its second quarter ended April 30, and reports on its recently concluded strategic
|
| Haemacure and Angiotech Enter License, Distribution and Supply Agreements for Haemacure's All-Human Fibrin Sealant and Thrombin Products |
3rd June, 2009 |
HAEMACURE CORPORATION |
HAE:TSX
Haemacure Completes US$2.5 Million Bridge Financing from Angiotech
MONTREAL, June 3 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio
|
| Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation |
3rd June, 2009 |
Angiotech Pharmaceuticals, Inc. |
Angiotech to Provide $2.5 Million Bridge Facility to Haemacure
VANCOUVER, June 3 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a specialty pharmaceutical and
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 555 times since April 2007, the link to the organisation's website has been followed 57 times Recent Search Terms used to find this page: tsx hae | haemacure e-mail | Haemacure Corp and therapeutics | Haemacure Corp and therapeutics | haemacure | Haemacure Corp | haemacure | haemacure | joseph galli HAEMACURE email | haemacure corporation oct. 2009 | . Search for more companies in Braintree Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Haemacure Corporation |
